Abstract:To reduce time and cost, virtual ligand screening (VLS) often precedes experimental ligand screening in modern drug discovery. Traditionally, high-resolution structure-based docking approaches rely on experimental structures, while ligand-based approaches need known binders to the target protein and only explore their nearby chemical space. In contrast, our structure-based FINDSITEcomb2.0 approach takes advantage of predicted, low-resolution structures and information from ligands that bind distantly related proteins whose binding sites are similar to the target protein. Using a boosted tree regression machine learning framework, we significantly improved FINDSITEcomb2.0 by integrating ligand fragment scores as encoded by molecular fingerprints with the global ligand similarity scores of FINDSITEcomb2.0. The new approach, FRAGSITE, exploits our observation that ligand fragments, e.g., rings, tend to interact with stereochemically conserved protein subpockets that also occur in evolutionarily unrelated proteins. FRAGSITE was benchmarked on the 102 protein DUD-E set, where any template protein whose sequence identify >30% to the target was excluded. Within the top 100 ranked molecules, FRAGSITE improves VLS precision and recall by 14.3 and 18.5%, respectively, relative to FINDSITEcomb2.0. Moreover, the mean top 1% enrichment factor increases from 25.2 to 30.2. On average, both outperform state-of-the-art deep learning-based methods such as AtomNet. On the more challenging unbiased set LIT-PCBA, FRAGSITE also shows better performance than ligand similarity-based and docking approaches such as two-dimensional ECFP4 and Surflex-Dock v.3066. On a subset of 23 targets from DEKOIS 2.0, FRAGSITE shows much better performance than the boosted tree regression-based, vScreenML scoring function. Experimental testing of FRAGSITE's predictions shows that it has more hits and covers a more diverse region of chemical space than FINDSITEcomb2.0. For the two proteins that were experimentally tested, DHFR, a well-studied protein that catalyzes the conversion of dihydrofolate to tetrahydrofolate, and the kinase ACVR1, FRAGSITE identified new small-molecule nanomolar binders. Interestingly, one new binder of DHFR is a kinase inhibitor predicted to bind in a new subpocket. For ACVR1, FRAGSITE identified new molecules that have diverse scaffolds and estimated nanomolar to micromolar affinities. Thus, FRAGSITE shows significant improvement over prior state-of-the-art ligand virtual screening approaches. A web server is freely available for academic users at <a class="extLink" href="http://http:/sites.gatech.edu/cssb/FRAGSITE">http:/sites.gatech.edu/cssb/FRAGSITE</a>.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jcim.0c01160?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jcim.0c01160</a>.Additional information for experimental methods and (Tables S1 and S2) top 40 most frequent fragments in DrugBank drugs and performance of methods for individual DUD-E targets using the modeled target structure (<a class="ext-link" href="/doi/suppl/10.1021/acs.jcim.0c01160/suppl_file/ci0c01160_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Fragment-based screening of enzyme drug targets : Microfluidic mobility shift assay improves confidence in candidate selection

Fragment-based Drug Discovery and Molecular Docking in Drug Design.

Fragment Databases from Screened Ligands for Drug Discovery (FDSL-DD).

Streamlining Computational Fragment-Based Drug Discovery Through Evolutionary Optimization Informed by Ligand-Based Virtual Prescreening

Fragment-based target screening as an empirical approach to prioritising targets: a case study on antibacterials

Extending the Detection Limit in Fragment Screening of Proteins Using Reverse Micelle Encapsulation

Efficient large-scale exploration of fragment hit progression by exploiting binding-site purification of actives (B-SPA) through combining multi-step array synthesis and HT crystallography.

How to Find a Fragment: Methods for Screening and Validation in Fragment‐Based Drug Dscovery

A fragment based competitive 19F LB‐NMR platform for hotspot directed ligand profiling

Ligand and Target Discovery by Fragment-Based Screening in Human Cells

FRAGSITE: A Fragment-Based Approach for Virtual Ligand Screening

An efficient and information-rich biochemical method design for fragment library screening on ion channels

Fragment-based design of selective GPCR ligands guided by free energy simulations

Target-based drug discovery: Applications of fluorescence techniques in high throughput and fragment-based screening

Covalent fragment-based drug discovery for target tractability

Exploring protein hotspots by optimized fragment pharmacophores

FMOPhore for hotspot identification and efficient fragment-to-lead growth strategies

In silico Strategies to Support Fragment-to-Lead Optimization in Drug Discovery

A Novel NMR-Based Protocol to Screen Ultralow Molecular Weight Fragments

Fragmenstein: predicting protein-ligand structures of compounds derived from known crystallographic fragment hits using a strict conserved-binding–based methodology

A comparative study of fragment screening methods on the p38α kinase: new methods, new insights